{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:13:54Z","timestamp":1771373634823,"version":"3.50.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre Poland","doi-asserted-by":"publisher","award":["UMO-2018\/31\/F\/NZ1\/03891"],"award-info":[{"award-number":["UMO-2018\/31\/F\/NZ1\/03891"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.virol.2024.110218","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T11:12:46Z","timestamp":1725361966000},"page":"110218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["TMPRSS2-specific antisense oligonucleotides inhibit host cell entry of emerging viruses"],"prefix":"10.1016","volume":"600","author":[{"given":"Rafal","family":"Nowak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Gazecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryszard","family":"Kierzek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"P\u00f6hlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2012-7223","authenticated-orcid":false,"given":"Pawel","family":"Zmora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2024.110218_bib1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/cells9010137","article-title":"RNA-based therapeutics: from antisense oligonucleotides to miRNAs","volume":"9","author":"Bajan","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.virol.2024.110218_bib2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/microorganisms11010183","article-title":"Influenza treatment: limitations of antiviral therapy and advantages of drug combination therapy","volume":"11","author":"Batool","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.virol.2024.110218_bib3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.virol.2024.110218_bib4","doi-asserted-by":"crossref","first-page":"10016","DOI":"10.1128\/JVI.00239-10","article-title":"TMPRSS2 and TMPRSS4 facilitate trypsin-independent spread of influenza virus in Caco-2 cells","volume":"84","author":"Bertram","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110218_bib5","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202000786","article-title":"TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells","volume":"3","author":"Bestle","year":"2020","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.virol.2024.110218_bib6","doi-asserted-by":"crossref","first-page":"9896","DOI":"10.1128\/JVI.01118-06","article-title":"Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium","volume":"80","author":"B\u00f6ttcher","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110218_bib7","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1128\/JVI.01294-10","article-title":"Inhibition of influenza virus infection in human airway cell cultures by an antisense peptide-conjugated morpholino oligomer targeting the hemagglutinin-activating protease TMPRSS2","volume":"85","author":"B\u00f6ttcher-Friebertsh\u00e4user","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110218_bib8","doi-asserted-by":"crossref","first-page":"7967","DOI":"10.1021\/bi0343774","article-title":"RNA interference in mammalian cells by chemically-modified RNA","volume":"42","author":"Braasch","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.virol.2024.110218_bib9","doi-asserted-by":"crossref","first-page":"23177","DOI":"10.1074\/jbc.R109.021006","article-title":"Type II transmembrane serine proteases","volume":"284","author":"Bugge","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.virol.2024.110218_bib10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.molmed.2009.05.003","article-title":"Type II transmembrane serine proteases in cancer and viral infections","volume":"15","author":"Choi","year":"2009","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.virol.2024.110218_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.618651","article-title":"Generation of SARS-CoV-2 spike pseudotyped virus for viral entry and neutralization assays: a 1-week protocol","volume":"7","author":"Condor Capcha","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.virol.2024.110218_bib12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0022-2836(74)90560-9","article-title":"The molecular mechanism of thermal unfolding of Escherichia coli formylmethionine transfer RNA","volume":"87","author":"Crothers","year":"1974","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.virol.2024.110218_bib13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1101\/gad.6.1.135","article-title":"A 5\u2019-terminal stem-loop structure can stabilize mRNA in Escherichia coli","volume":"6","author":"Emory","year":"1992","journal-title":"Genes Dev."},{"key":"10.1016\/j.virol.2024.110218_bib14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3390\/v14020389","article-title":"In silico analysis and Synthesis of nafamostat derivatives and evaluation of their anti-SARS-CoV-2 activity","volume":"14","author":"Fujimoto","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2024.110218_bib15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.virol.2024.110218_bib16","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1128\/JVI.00128-13","article-title":"The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies","volume":"87","author":"Gierer","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110218_bib17","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1128\/JVI.02232-10","article-title":"Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response","volume":"85","author":"Glowacka","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110218_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100849","article-title":"Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial","volume":"35","author":"Gunst","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.virol.2024.110218_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003774","article-title":"Tmprss2 is essential for influenza H1N1 virus pathogenesis in mice","volume":"9","author":"Hatesuer","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2024.110218_bib20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1017\/S0033583506004215","article-title":"RNA structural motifs: building blocks of a modular biomolecule","volume":"38","author":"Hendrix","year":"2005","journal-title":"Q. Rev. Biophys."},{"key":"10.1016\/j.virol.2024.110218_bib21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virol.2024.110218_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00754-20","article-title":"Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19","volume":"64","author":"Hoffmann","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2024.110218_bib23","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1038\/s41467-022-33911-8","article-title":"Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways","volume":"13","author":"Iwata-Yoshikawa","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2024.110218_bib24","doi-asserted-by":"crossref","first-page":"e01815","DOI":"10.1128\/JVI.01815-18","article-title":"TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection","volume":"93","author":"Iwata-Yoshikawa","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110218_bib25","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1093\/nar\/gkl232","article-title":"Nearest neighbor parameters for Watson\u2013Crick complementary heteroduplexes formed between 2\u2032-O-methyl RNA and RNA oligonucleotides","volume":"34","author":"Kierzek","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.virol.2024.110218_bib26","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1128\/MCB.26.3.965-975.2006","article-title":"Phenotypic analysis of mice lacking the tmprss2-encoded protease","volume":"26","author":"Kim","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.virol.2024.110218_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00452-22","article-title":"A double-blind, randomized, placebo-controlled, phase II clinical study to evaluate the efficacy and safety of camostat mesylate (DWJ1248) in adult patients with mild to moderate COVID-19","volume":"67","author":"Kim","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2024.110218_bib28","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1186\/s12916-022-02518-7","article-title":"A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)","volume":"20","author":"Kinoshita","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.virol.2024.110218_bib29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12985-020-01323-z","article-title":"H2 influenza A virus is not pathogenic in Tmprss2 knock-out mice","volume":"17","author":"Lambertz","year":"2020","journal-title":"Virol. J."},{"key":"10.1016\/j.virol.2024.110218_bib30","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1099\/jgv.0.001274","article-title":"Tmprss2 knock-out mice are resistant to H10 influenza A virus pathogenesis","volume":"100","author":"Lambertz","year":"2019","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2024.110218_bib31","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1099\/jgv.0.001128","article-title":"Exchange of amino acids in the H1-haemagglutinin to H3 residues is required for efficient influenza A virus replication and pathology in Tmprss2 knock-out mice","volume":"99","author":"Lambertz","year":"2018","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2024.110218_bib32","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/BF01718208","article-title":"Evaluation of anti-influenza effects of camostat in mice infected with non-adapted human influenza viruses","volume":"141","author":"Lee","year":"1996","journal-title":"Arch. Virol."},{"key":"10.1016\/j.virol.2024.110218_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00970-21","article-title":"The TMPRSS2 inhibitor nafamostat reduces SARS-CoV-2 pulmonary infection in mouse models of COVID-19","volume":"12","author":"Li","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.virol.2024.110218_bib34","first-page":"111","volume":"vol. 5","author":"Li","year":"2014"},{"key":"10.1016\/j.virol.2024.110218_bib35","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1093\/nar\/gkz500","article-title":"mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway","volume":"47","author":"Liang","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.virol.2024.110218_bib36","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.virol.2024.110218_bib37","doi-asserted-by":"crossref","first-page":"12658","DOI":"10.1128\/JVI.01542-10","article-title":"Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2","volume":"84","author":"Matsuyama","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110218_bib38","doi-asserted-by":"crossref","first-page":"L657","DOI":"10.1152\/ajplung.00509.2016","article-title":"Human airway trypsin-like protease, a serine protease involved in respiratory diseases","volume":"312","author":"Menou","year":"2017","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.virol.2024.110218_bib39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41581-022-00642-4","article-title":"Therapeutic advances in COVID-19","volume":"19","author":"Murakami","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.virol.2024.110218_bib40","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1038\/s41596-020-0394-5","article-title":"Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay","volume":"15","author":"Nie","year":"2020","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.virol.2024.110218_bib41","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.omtn.2019.12.018","article-title":"RNA secondary structure motifs of the influenza A virus as targets for siRNA-mediated RNA interference","volume":"19","author":"Piasecka","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.virol.2024.110218_bib42","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1021\/jm050044o","article-title":"Positional effect of chemical modifications on short interference RNA activity in mammalian cells","volume":"48","author":"Prakash","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.virol.2024.110218_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0281281","article-title":"Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection","volume":"18","author":"Qiao","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2024.110218_bib44","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13776","article-title":"Aprotinin treatment against SARS-CoV-2: a randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19","volume":"52","author":"Redondo-Calvo","year":"2022","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.virol.2024.110218_bib45","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201181","article-title":"Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses","volume":"217","author":"Schmidt","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.virol.2024.110218_bib46","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.3390\/jcm12206618","article-title":"RAndomized clinical trial of NAfamostat mesylate, A potent transmembrane protease serine 2 (TMPRSS2) inhibitor, in patients with COVID-19 pneumonia","volume":"12","author":"Seccia","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.virol.2024.110218_bib47","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41586-022-04661-w","article-title":"A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic","volume":"605","author":"Shapira","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110218_bib48","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1080\/17460441.2017.1372417","article-title":"Type II transmembrane serine proteases as potential target for anti-influenza drug discovery","volume":"12","author":"Shin","year":"2017","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.virol.2024.110218_bib49","doi-asserted-by":"crossref","first-page":"12552","DOI":"10.1128\/JVI.01890-13","article-title":"Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2","volume":"87","author":"Shirato","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110218_bib50","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1128\/JVI.02062-10","article-title":"A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry","volume":"85","author":"Shulla","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110218_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/viro.1999.9716","article-title":"Role of hemagglutinin cleavage for the pathogenicity of influenza virus","volume":"258","author":"Steinhauer","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.virol.2024.110218_bib52","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00018-005-5558-5","article-title":"Hairpin RNA: a secondary structure of primary importance","volume":"63","author":"Svoboda","year":"2006","journal-title":"Cell. Mol. Life Sci. CMLS"},{"key":"10.1016\/j.virol.2024.110218_bib53","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3390\/pathogens9110925","article-title":"RNA secondary structure as a First step for rational design of the oligonucleotides towards inhibition of influenza A virus replication","volume":"9","author":"Szabat","year":"2020","journal-title":"Pathog. Basel Switz"},{"key":"10.1016\/j.virol.2024.110218_bib54","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1160\/TH03-02-0071","article-title":"Type II transmembrane serine proteases","volume":"90","author":"Szabo","year":"2003","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.virol.2024.110218_bib55","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1128\/JVI.03799-13","article-title":"TMPRSS2 is a host factor that is essential for pneumotropism and pathogenicity of H7N9 influenza A virus in mice","volume":"88","author":"Tarnow","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110218_bib56","first-page":"628","article-title":"Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial","volume":"122","author":"Tobback","year":"2022","journal-title":"Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis."},{"key":"10.1016\/j.virol.2024.110218_bib57","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/346613a0","article-title":"Tetraloops and RNA folding","volume":"346","author":"Uhlenbeck","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110218_bib58","doi-asserted-by":"crossref","first-page":"14719","DOI":"10.1021\/bi9809425","article-title":"Thermodynamic parameters for an expanded nearest-neighbor model for formation of RNA duplexes with Watson-Crick base pairs","volume":"37","author":"Xia","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.virol.2024.110218_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1125246","article-title":"The development of COVID-19 treatment","volume":"14","author":"Yuan","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2024.110218_bib60","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3390\/vaccines8030386","article-title":"Rapid quantification of SARS-CoV-2-neutralizing antibodies using propagation-defective vesicular stomatitis virus pseudotypes","volume":"8","author":"Zettl","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.virol.2024.110218_bib61","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2011.07.014","article-title":"Aprotinin and similar protease inhibitors as drugs against influenza","volume":"92","author":"Zhirnov","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2024.110218_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101169","article-title":"Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial","volume":"41","author":"Zhuravel","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.virol.2024.110218_bib63","doi-asserted-by":"crossref","first-page":"12087","DOI":"10.1128\/JVI.01427-14","article-title":"DESC1 and MSPL activate influenza A viruses and emerging coronaviruses for host cell entry","volume":"88","author":"Zmora","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110218_bib64","doi-asserted-by":"crossref","first-page":"13863","DOI":"10.1074\/jbc.RA118.001273","article-title":"TMPRSS11A activates the influenza A virus hemagglutinin and the MERS coronavirus spike protein and is insensitive against blockade by HAI-1","volume":"293","author":"Zmora","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.virol.2024.110218_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138380","article-title":"TMPRSS2 isoform 1 activates respiratory viruses and is expressed in viral target cells","volume":"10","author":"Zmora","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2024.110218_bib66","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3390\/v14040704","article-title":"Effect of short time of SARS-CoV-2 infection in caco-2 cells","volume":"14","author":"Zupin","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2024.110218_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105768","article-title":"Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: systematic review and network meta-analysis","volume":"221","author":"Zur","year":"2024","journal-title":"Antivir. Res."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224002393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224002393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:33:37Z","timestamp":1764599617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682224002393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":67,"alternative-id":["S0042682224002393"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2024.110218","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TMPRSS2-specific antisense oligonucleotides inhibit host cell entry of emerging viruses","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2024.110218","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110218"}}